Clinical Trial Update | 5-year follow-up validates efficacy of sorafenib maintenance in FLT3-ITD AML

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary on Twitter

NEW: with over 5 years of follow-up, sorafenib maintenance is associated with improved outcomes compared w/ non-maintenance in patients w/ FLT3-ITD AML undergoing allogeneic HSCT in a multicentre, randomised, ph 3 trial #leusm #bmtsm https://t.co/JK190vS0Ql pic.twitter.com/SBP887hgEu

— The Lancet Haematology (@TheLancetHaem) July 5, 2023